437 related articles for article (PubMed ID: 31960730)
41. Prognosis and treatment of Waldenström's macroglobulinemia.
Louw VJ; Webb MJ
Transfus Apher Sci; 2010 Apr; 42(2):193-7. PubMed ID: 20117052
[TBL] [Abstract][Full Text] [Related]
42. What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo JJ; Treon SP
Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
[TBL] [Abstract][Full Text] [Related]
43. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
[TBL] [Abstract][Full Text] [Related]
44. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N; Dhodapkar MV
Clin Adv Hematol Oncol; 2009 Oct; 7(10):677-81, 687-90. PubMed ID: 20040909
[TBL] [Abstract][Full Text] [Related]
45. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
46. Waldenström's macroglobulinemia as a diagnostic challenge: case report.
Budimir I; Nikolić M; Pusić MS; Hrabar D; Ljubicić N; Duvnjak M; Supanc V; Nikolac I; Babić N; Sokcević M
Acta Clin Croat; 2014 Mar; 53(1):94-7. PubMed ID: 24974671
[TBL] [Abstract][Full Text] [Related]
47. Management of Waldenström macroglobulinemia in 2020.
Castillo JJ; Treon SP
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):372-379. PubMed ID: 33275726
[TBL] [Abstract][Full Text] [Related]
48. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
Amaador K; Kersten MJ; Minnema MC; Vos JMI
Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
[TBL] [Abstract][Full Text] [Related]
49. SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.
Thomas SK
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):347-355. PubMed ID: 34980578
[TBL] [Abstract][Full Text] [Related]
50. Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D; Tam CS; Joshua D; Ho JP; Szer J; Quach H; Spencer A; Harrison S; Mollee P; Roberts AW; Horvath N; Lee C; Zannettino A; Brown R; Augustson B; Jaksic W; Gibson J; Kalff A; Johnston A; Trotman J; Kalro A; Grigoriadis G; Ward C; Prince HM
Intern Med J; 2017 Jan; 47(1):35-49. PubMed ID: 28076910
[TBL] [Abstract][Full Text] [Related]
51. Are you sure this is Waldenstrom macroglobulinemia?
Ghobrial IM
Hematology Am Soc Hematol Educ Program; 2012; 2012():586-94. PubMed ID: 23233639
[TBL] [Abstract][Full Text] [Related]
52. How I treat Waldenström macroglobulinemia.
Treon SP
Blood; 2015 Aug; 126(6):721-32. PubMed ID: 26002963
[TBL] [Abstract][Full Text] [Related]
53. JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-3. Lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia (LPL/WM).
Kobayashi Y
Int J Hematol; 2019 Nov; 110(5):524-528. PubMed ID: 31494831
[No Abstract] [Full Text] [Related]
54. Treatment of Waldenstrom's Macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A
Curr Treat Options Oncol; 2007 Apr; 8(2):144-53. PubMed ID: 17634838
[TBL] [Abstract][Full Text] [Related]
55. [Waldenström's macroglobulinemia].
Watanabe R
Rinsho Ketsueki; 2015 Oct; 56(10):2074-85. PubMed ID: 26458447
[TBL] [Abstract][Full Text] [Related]
56. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines.
Ansell SM; Kyle RA; Reeder CB; Fonseca R; Mikhael JR; Morice WG; Bergsagel PL; Buadi FK; Colgan JP; Dingli D; Dispenzieri A; Greipp PR; Habermann TM; Hayman SR; Inwards DJ; Johnston PB; Kumar SK; Lacy MQ; Lust JA; Markovic SN; Micallef IN; Nowakowski GS; Porrata LF; Roy V; Russell SJ; Short KE; Stewart AK; Thompson CA; Witzig TE; Zeldenrust SR; Dalton RJ; Rajkumar SV; Gertz MA
Mayo Clin Proc; 2010 Sep; 85(9):824-33. PubMed ID: 20702770
[TBL] [Abstract][Full Text] [Related]
57. Waldenström macroglobulinemia: 2013 update on diagnosis, risk stratification, and management.
Gertz MA
Am J Hematol; 2013 Aug; 88(8):703-11. PubMed ID: 23784973
[TBL] [Abstract][Full Text] [Related]
58. A survey on diagnostic methods and treatment strategies used in patients with Waldenström's macroglobulinaemia in The Netherlands.
Klodzinska S; Vos JM; Kersten MJ; Wijermans P; Minnema MC
Neth J Med; 2013 Mar; 71(2):90-6. PubMed ID: 23462060
[TBL] [Abstract][Full Text] [Related]
59. Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.
Pangalis GA; Kyrtsonis MC; Kontopidou FN; Siakantaris MP; Dimopoulou MN; Vassilakopoulos TP; Tzenou T; Kokoris S; Dimitriadou E; Kalpadakis C; Tsalimalma K; Tsaftaridis P; Panayiotidis P; Angelopoulou MK
Clin Lymphoma; 2005 Mar; 5(4):235-40. PubMed ID: 15794855
[TBL] [Abstract][Full Text] [Related]
60. Lymphoplasmacytic lymphoma with IgA paraproteinemia mimicking Waldenstrom's Macroglobulinemia.
Basu D; Pathak D; Shyambabu C; Koner BC; Swaminathan RP
Indian J Pathol Microbiol; 2004 Oct; 47(4):515-7. PubMed ID: 16295380
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
